ReviewBioMed research international2018
The Role of Galectins in Cervical Cancer Biology and Progression.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 56 citations in OpenAlex.
- Mechanism of N6-methyladenosine (m6A)-mediated upregulation of LINC00958 in the growth of cervical cancer.Frontiers in oncology · 2026Article
- DNA hypomethylation modification promotes BST2 expression in cervical cancer by facilitating STAT1 binding to the promoter of BST2.Infectious agents and cancer · 2025Article
- Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.Biomarker research · 2025Review
- Leveraging FAM features to predict the prognosis of LGG patients and immunotherapy outcome.American journal of cancer research · 2024Article
- Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity.Journal of Cancer · 2024Article
- Article
- TIME Is Ticking for Cervical Cancer.Biology · 2023Review
- Astragaloside IV suppresses the migration and EMT progression of cervical cancer cells by inhibiting macrophage M2 polarization through TGFβ/Smad2/3 signaling.Functional & integrative genomics · 2023Article
- Review
- Variants Identified in theGenes · 2023Article
- TMEM33 as a Prognostic Biomarker of Cervical Cancer and Its Correlation with Immune Infiltration.Mediators of inflammation · 2023Article
- Galectins: Important Regulators in Normal and Pathologic Pregnancies.International journal of molecular sciences · 2022Review
- LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K/AKT pathway.Gland surgery · 2022Article
- Alteration of Gene and miRNA Expression in Cervical Intraepithelial Neoplasia and Cervical Cancer.International journal of molecular sciences · 2022Article
- The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review).Molecular medicine reports · 2022Article
- Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression.World journal of gastroenterology · 2022Review
- Epidemiological Trends and Attributable Risk Burden of Cervical Cancer: An Observational Study from 1990 to 2019.International journal of clinical practice · 2022Observational
- Response to Article "Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages" [Letter].OncoTargets and therapy · 2022Article
- Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages.OncoTargets and therapy · 2022Article
- Machine Learning-Assisted Ensemble Analysis for the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is one of the malignant tumors with high incidence and high mortality among women in developing countries. The main factors affecting the prognosis of cervical cancer are the late recurrence and metastasis and the effective adjuvant treatment, which is radiation and chemotherapy or combination therapy. Galectins, a family containing many carbohydrate binding proteins, are closely involved in the occurrence and development of tumor. They are involved in tumor cells transformation, angiogenesis, metastasis, immune escape, and sensitivity against radiation and chemotherapy. Therefore, galectins are deemed as the targets of multifunctional cancer treatment. In this review, we mainly focus on the role of galectins, especially galectin-1, galectin-3, galectin-7, and galectin-9 in cervical cancer, and provide theoretical basis for potential targeted treatment of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.